Bimatoprost sustained-release implant shows positive phase 3 data

A bimatoprost sustained-release implant reduced IOP by approximately 30% over 12 weeks in a phase 3 clinical study, according to an Allergan press release.
The multicenter, randomized, masked, parallel-group study, which included 594 subjects with open-angle glaucoma or ocular hypertension, compared the efficacy and safety of two dose strengths of Bimatoprost SR and timolol eye drops used twice daily for up to 20 months. The study showed the majority of patients treated with Bimatoprost SR were potentially able to be treatment-free for 1 year after the last implant was inserted, (Read more...)

Full Story →